Senior Correspondent, London
Ben's Feed
Sep 28, 2014

Roche breast cancer drug shows “unprecedented” survival benefit

MADRID, Sept 28 (Reuters) – A new breast cancer drug from
Roche has shown “unprecedented” survival benefits in a
clinical trial, boosting prospects for its widespread use in
women with an aggressive form of the disease.

Patients with a type of breast cancer known as HER-2
positive, which makes up about a quarter of all breast cancers,
who were given Perjeta on top of older medicine Herceptin and
chemotherapy lived 15.7 months longer than those on Herceptin
and chemotherapy alone.

Sep 28, 2014

No benefit from continued use of AstraZeneca’s Iressa drug

MADRID, Sept 28 (Reuters) – Continuing to give AstraZeneca’s
drug Iressa plus chemotherapy to lung cancer patents
whose disease has worsened after previously taking the medicine
on its own does not provide any benefit.

Some doctors had hoped that extending the use of Iressa in
combination with chemotherapy would help to keep cancers at bay,
even when tumour cells had started to develop resistance to the
drug.

Sep 27, 2014
Sep 27, 2014
Sep 27, 2014

Early data promising for AstraZeneca cancer drug combination

MADRID, Sept 27 (Reuters) – Early results for a closely
watched cancer drug combination from AstraZeneca that
boosts the immune system suggest the cocktail is promising,
though limited patient numbers mean the data is far from
conclusive.

The British drugmaker, which fended off a $118 billion
takeover bid from Pfizer in May in part by talking up
its cancer drug prospects, has high hopes for the combination of
two experimental drugs known as MEDI4736 and tremelimumab.

Sep 27, 2014
Sep 25, 2014
Sep 25, 2014

GlaxoSmithKline appoints RBS’s Hampton as next chairman

LONDON (Reuters) – GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland (RBS.L: Quote, Profile, Research, Stock Buzz), as its next chairman.

Hampton will be taking the helm at Britain’s biggest drugmaker at a testing time. GSK was hit last week by a record $489 million fine in China for bribing doctors and has warned on profits in 2014 due to weak sales of its core respiratory drugs.

Sep 24, 2014

GSK to name RBS’s Hampton as new chairman this week

LONDON, Sept 24 (Reuters) – Drugmaker GlaxoSmithKline
will this week name Philip Hampton, who currently chairs
Royal Bank of Scotland, as its next chairman, a person
close to the process said on Wednesday.

Hampton is expected to join the GSK board as a non-executive
director late this year or early in 2015 and take over from
current chairman Chris Gent around the middle of next year.

Sep 24, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben